Prescribing Advice for GPs

An NHS Prescribing Advisers' Blog

SMC October Update

The Scottish Medicines Consortium (SMC) has issued its monthly advice on new medicines.

Sitagliptin (Januvia®) has been accepted for use in combination with a sulphonylurea or sulphonylurea and metformin in patients with type 2 diabetes who fail to achieve adequate glucose control while taking maximal tolerated doses.

Duloxetine (Cymbalta®) has been rejected for use in generalised anxiety disorder in the absence of a submission from the manufacturer.

Action: Clinicians should be aware of the recommendations of the SMC. Routine use of rejected and restricted medicines should be avoided.

Share 'SMC October Update' on Email Share 'SMC October Update' on Delicious Share 'SMC October Update' on Digg Share 'SMC October Update' on Facebook Share 'SMC October Update' on Google+ Share 'SMC October Update' on reddit Share 'SMC October Update' on StumbleUpon Share 'SMC October Update' on Twitter

atomic-wealth

No Comments to “SMC October Update”

Leave a Comment

(required)

(required)


Prescribing Advice for GPs is powered by WordPress.
Subscribe for Free to our RSS or Atom Feeds for New Entries.
Akismet has protected Prescribing Advice for GPs from 789,658 spam comments.

atomic-wealth
fond-illness
summer